Incidence of Engraftment Syndrome in Classical Hodgkin Lymphoma after Checkpoint Inhibitors: A Retrospective Analysis Read more
Transcriptional Profiles of CD19 Chimeric Antigen Receptor (CAR) T-cells that Induce Durable Remission in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Read more
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia Read more
“Clinico-genomic Predictors of Outcomes Among Patients with HIV or Paraneoplastic Syndromes and Cancer” Read more
Tafasitamab, Lenalidomide and Venetoclax Combination Therapy for Relapsed or Refractory Mantle Cell Lymphoma (V-MIND): A Phase II Study with Safety Lead-in Read more
A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma ALPHA3) Read more
Outcomes among Adult Recipients of CAR T-Cell Therapeutics for Burkitt and Burkitt-like Lymphoma Read more
Outcomes of Patients with Relapsed/Refractory Hodgkin Lymphoma Treated with PD-1 Inhibitors Outside of Clinical Trials Read more
